Mantle Cell Lymphoma Market

Key Findings

• As per Lynch et al., (2022), Mantle Cell Lymphoma is a rare subtype of B-cell non-Hodgkin lymphoma (NHL) with an annual incidence of one case per 200,000 people. MCL comprises around 5% of all.

• Mantle Cell Lymphoma Market Companies are working in the market are Juno Therapeutics, Nurix, Janssen Biotech, AbbVie/Genentech, TG Therapeutics, Roche, Eli Lilly and Company, Takeda Oncology, Starton Therapeutics, Incyte Corporation, BeiGene, Newave Pharmaceutical, Eli Lilly and Company, and others.

• Mantle Cell Lymphoma epidemiology is segmented as Total Mantle cell lymphoma Incident Cases, Total Mantle cell lymphoma Diagnosed Cases, Total Mantle cell lymphoma Gender-specific Cases, Total Mantle cell lymphoma Age-specific Cases, Total Mantle cell lymphoma Stage-specific Cases, and Total Mantle cell lymphoma Treated Cases in the Mantle Cell Lymphoma market report.

Request a sample to unlock the CAGR for Mantle Cell Lymphoma Market

DelveInsight's "Mantle Cell Lymphoma Market Insights, Epidemiology, and Market Forecast — 2032" report delivers an in-depth understanding of the Mantle cell lymphoma, historical and forecasted epidemiology as well as the Mantle Cell Lymphoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2019 to 2032.

The Mantle Cell Lymphoma market report provides current treatment practices, emerging drugs, Mantle Cell Lymphoma market share of the individual therapies, current and forecasted Mantle Cell Lymphoma market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Mantle Cell Lymphoma treatment practice/algorithm, and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032

Mantle Cell Lymphoma Market Disease: Understanding and Treatment Algorithm

Mantle cell lymphoma, is one of the most aggressive type of lymphoma, with relatively short responses to therapy, and is a B-cell lymphoma that develops from malignant B-lymphocytes within a region of the lymph node known as the mantle zone. It takes over body’s B Cells, which normally make antibodies to fight infections and the cancerous B cells grow out of control and make lymph nodes larger. The cancer can spread to patient’s bone marrow, liver, and gastrointestinal tract as well. The exact underlying cause of Mantle Cell Lymphoma is unknown. However, approximately 85% of people with the condition have a genetic change, or mutation, in chromosomes 11 and 14. Short segments of these chromosomes may exchange places. The exchange occurs at the site of the cyclin D1 gene on chromosome 11 and the site of a gene that controls the formation of antibody molecules on chromosome 14.

Commonly seen complications from disease progression includes low blood cell count, low numbers of platelets. Gastrointestinal, pulmonary, or central nervous system (CNS) complications are also seen as Mantle cell lymphoma is extranodal. Although there is a lack of agreement in the medical literature on specific risk factors for Mantle cell lymphoma but family history and certain genetic changes have been identified that increase the risk. It has been observed that it affects males about four times as commonly as females. Apart from that Age is a risk factor; the median age of Mantle cell lymphoma onset is 60 years of age with an age range of 35-85 years.

Mantle Cell Lymphoma Diagnosis

Mantle Cell Lymphoma is diagnosed based upon a detailed patient history, thorough clinical evaluation and a variety of tests, including a biopsy of an affected lymph node or the bone marrow, blood tests, PET/CT scan and imaging tests like CAT.

There are 4 stages in Mantle Cell Lymphoma and staging determines extent of disease, or how much the cancer has spread, and where it is located. It helps doctors to develop a prognosis and tailor treatment to individual patients and minimize potential toxic effects of therapy.

Mantle Cell Lymphoma Treatment

The Treatment depends upon the severity and spread rate of the disease. Certain therapies are used to treat Mantle Cell Lymphoma which includes chemotherapy, immunotherapy, radiation therapy, CART – Cell therapy. If the patient doesn’t respond to these, targeted therapies are used. Stem cell therapy is suggested only if lymphoma is aggressive or returns after treatment.

Mantle Cell Lymphoma Epidemiology

The Mantle Cell Lymphoma epidemiology section provides insights about historical and current Mantle cell lymphoma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

• As per Lynch et al., (2022), Mantle Cell Lymphoma is a rare subtype of B-cell non-Hodgkin lymphoma (NHL) with an annual incidence of one case per 200,000 people. MCL comprises around 5% of all.

• The disease epidemiology covered in the report provides historical as well as forecasted Mantle Cell Lymphoma epidemiology [segmented as Total Incident Cases of Mantle cell lymphoma, Total Diagnosed Cases of Mantle cell lymphoma, Total Gender-specific Cases of Mantle cell lymphoma, Total Age-specific Cases of Mantle cell lymphoma, Total Stage-specific Cases of Mantle cell lymphoma, and Total Treated Cases of Mantle cell lymphoma] in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

Country Wise- Mantle Cell Lymphoma Epidemiology

This section provides glimpse of the Mantle Cell Lymphoma epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Learn more about the evolving epidemiology trends and key developments: Mantle Cell Lymphoma Epidemiology Forecast

Mantle Cell Lymphoma Drug Chapters

The drug chapter segment of the Mantle Cell Lymphoma report encloses the detailed analysis of Mantle Cell Lymphoma marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Mantle Cell Lymphoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Mantle Cell Lymphoma Marketed Drugs

BRUKINSA (zanubrutinib): BeiGene

BRUKINSA (zanubrutinib) is a small-molecule inhibitor of BTK. Zanubrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. In November 2019, the Food and Drug Administration granted accelerated approval to zanubrutinib (BRUKINSA, BeiGene) for adult patients with Mantle Cell Lymphoma who have received at least one prior therapy.

IMBRUVICA (ibrutinib): Janssen Biotech

IMBRUVICA (ibrutinib) is an orally available, selective inhibitor of Bruton's tyrosine kinase (Btk). Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTK’s role in signaling through the B-cell surface receptors results in activation of pathways necessary for B-cell trafficking, chemotaxis, and adhesion. In November 2013, the Food and Drug Administration granted approval to ibrutinib for the treatment of patients with Mantle Cell Lymphoma who have received at least one prior therapy.

Note: Detailed Current therapies assessment will be provided in the full report of Mantle cell lymphoma

Mantle Cell Lymphoma Emerging Drugs

Pirtobrutinib is an investigational, oral, highly-selective non-covalent Bruton's tyrosine kinase (BTK) inhibitor. BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas including chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom’s macroglobulinemia, and marginal zone lymphoma. Pirtobrutinib was designed to reversibly bind BTK, deliver consistently high target coverage regardless of BTK turnover rate, preserve activity in the presence of the C481 acquired resistance mutations, and avoid off-target kinases that have complicated the development of both covalent and investigational non-covalent BTK inhibitors. It is currently being studied in multiple Mantle cell lymphoma clinical trials. Currently, the drug is in Phase III comparing pirtobrutinib to investigator's choice of ibrutinib, acalabrutinib or zanubrutinib in MCL patients who have received 1 or more lines of therapy and are BTK inhibitor naïve which is anticipated to be complete by April 2025.

NVG-111 is a first-in-class bispecific antibody T-cell engager for haematological and solid malignancies that targets the Receptor Tyrosine Kinase like Orphan like Receptor 1 (ROR1). The NVG-111 initiative will first concentrate on Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia. It is designed to be extremely efficient in killing cancer cells while sparing healthy B cells. NVG-111 can target cancer initiating stem cells (CSCs), a subpopulation of cancer cells that are resistant to standard cancer therapies and is believed to be the only T cell engager in development that can kill CSCs, potentially reducing the risk of tumor recurrence. Currently, the drug is in Phase I/II clinical trial which is anticipated to be complete by December 2023.

Note: Detailed emerging therapies assessment will be provided in the full report of Mantle cell lymphoma

Mantle Cell Lymphoma Market Outlook

The current treatment strategies for Mantle Cell Lymphoma primarily depends on multiple factors, including stage of disease, age of the patient, and patient’s overall health. Mantle Cell Lymphoma is usually diagnosed once it has spread throughout the body, and the majority of these patients require treatment. While Mantle Cell Lymphoma is considered as difficult cancer to treat, tremendous progress has been made in discovery of new treatments for the disease. In general, the current recommended mainstays for this specific cancer ailment includes Active Surveillance, Chemotherapy, Targeted therapy, and Transplantation.

For subset of patients who do not develop the symptoms and have a relatively small amount of slow-growing disease, active surveillance may be used as an acceptable option. With this strategy, patient’s overall health and disease are monitored through regular checkup visits and various evaluating procedures, such as laboratory and imaging tests. Active treatment is initiated if the patients begin to develop lymphoma related symptoms or there are signs that the disease is progressing based on testing during follow-up visits.

Initial treatment approaches for aggressive Mantle Cell Lymphoma in younger patients include combination chemotherapy, typically in combination with the monoclonal antibody rituximab (Rituxan) as a first-line treatment, though rituximab is not specifically approved by the US FDA for MCL. , followed by autologous stem cell transplantation (SCT, in which patients receive their own stem cells). Consolidation high-dose chemotherapy followed by autologous stem cell is often utilized to prolong remission in younger, medically fit patients. For older or less fit patients, less intensive chemotherapy followed by a prolonged course of rituximab alone, known as maintenance therapy, is often recommended.

Chemotherapeutic approaches used to treat Mantle Cell Lymphoma are:-

• R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)

• Bendamustine (treanda) in combination with rituximab

• Hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, dexamethasone alternating with high-dose methotrexate and cytarabine) + rituximab

Furthermore, allogeneic stem cell transplantation, in which patients receive stem cells from a related or unrelated donor, may increase response times for selected younger patients whose disease has relapsed (returned after treatment). Reduced-intensity transplants called non-myeloablative or mini-transplants are procedures in which stem cells are received from an allogeneic donor, but the chemotherapy or radiation administered prior to the transplant is less intense (i.e., just enough to allow the body to accept the donor cells). The transplanted cells recognize the cancer as a foreign invader and activate immune cells to destroy it. Patients receiving reduced-intensity transplants may avoid some of the side effects seen with high-dose chemotherapy coupled with fully ablative allogeneic SCT.

The dynamics of Mantle Cell Lymphoma market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the diseases, incremental healthcare spending across the world and expected launch of emerging therapies during the forecast period of 2022–2032. Companies across the globe are working towards the development of new treatment therapies for mantle cell lymphoma.

Some of the key players in the therapeutic market of MCL are Bristol-Myers Squibb (BMS), Takeda, Acerta Pharma/ AstraZeneca, and many others. Expected launch of emerging therapies such as, NVG-111 (Novalgen), HMPL-760 (Hutchison medipharma, Pirtobrutinib, Orelabrutinib (Beijing InnoCare Pharma Tech), LOXO-338 (Eli Lilly and Company), and others will significantly impact the Mantle Cell Lymphoma market during the forecast period (2022–2032).

Analyst Commentary

• The pipeline of Mantle Cell Lymphoma is very robust, many potential therapies are being investigated for the treatment of Mantle Cell Lymphoma, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.

• The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate, are likely to boost the growth of the Mantle Cell Lymphoma market in the 7MM. Aside from that, the market size of Mantle Cell Lymphoma may flourish due to increased research and development, label-expansion of approved therapies into other epilepsy in this field.

• The market growth of Mantle Cell Lymphoma may offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists.

Mantle Cell Lymphoma Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Mantle Cell Lymphoma market or expected to get launched in the market during the study period 2019-2032. The analysis covers Mantle Cell Lymphoma market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Note: Detailed emerging therapies assessment will be provided in the full report of Mantle cell lymphoma

Mantle Cell Lymphoma Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Mantle Cell Lymphoma key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Mantle Cell Lymphoma emerging therapies.

Learn more about the emerging therapies and key companies active in the therapeutics segment: Mantle Cell Lymphoma Pipeline Insight

Reimbursement Scenario in Mantle Cell Lymphoma

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs ' opinions working in Mantle Cell Lymphoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Mantle Cell Lymphoma market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitively and Market Intelligence analysis of the Mantle Cell Lymphoma Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Mantle Cell Lymphoma Market Report

• The report covers the descriptive overview of Mantle cell lymphoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
• Comprehensive insight has been provided into the Mantle Cell Lymphoma epidemiology and treatment in the 7MM
• The report assesses the disease risk and burden and highlights the unmet needs of Mantle Cell Lymphoma
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM by Total Incident Cases of Mantle Cell Lymphoma, Total Diagnosed Cases of Mantle Cell Lymphoma, Total Gender-specific Cases of Mantle Cell Lymphoma, Total Age-specific Cases of Mantle Cell Lymphoma, Total Stage-specific Cases of Mantle Cell Lymphoma, and Total Treated Cases of Mantle Cell Lymphoma.
• Detailed Patient Based Market Forecasting determines the trends shaping and driving the global Mantle Cell Lymphoma Market.

Mantle Cell Lymphoma Market Report Highlights

• In the coming years, the Mantle Cell Lymphoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Mantle Cell Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Mantle cell lymphoma. The launch of emerging therapies will significantly impact the Mantle Cell Lymphoma market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Mantle cell lymphoma
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed Mantle cell lymphoma clinical trial profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Mantle Cell Lymphoma Report Insights

• Patient Based Market Forecasting
• Therapeutic Approaches
• Mantle Cell Lymphoma Pipeline Analysis
• Mantle Cell Lymphoma Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Mantle Cell Lymphoma Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Mantle Cell Lymphoma Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Mantle Cell Lymphoma Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles

Key Questions

Market Insights:

• What was the Mantle Cell Lymphoma drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Mantle Cell Lymphoma total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings of the market across 7MM and which country will have the largest Mantle Cell Lymphoma market size during the forecast period (2019-2032)?
• At what CAGR, the Mantle Cell Lymphoma market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the Mantle Cell Lymphoma market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the Mantle Cell Lymphoma market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Mantle Cell Lymphoma?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• What is the historical Mantle Cell Lymphoma patient pool in seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• What would be the forecasted patient pool of Mantle Cell Lymphoma in seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about Mantle cell lymphoma?
• Out of all 7MM countries, which country would have the highest incident population of Mantle Cell Lymphoma during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the Mantle Cell Lymphoma treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Mantle Cell Lymphoma in the US, Europe, and Japan?
• What are the Mantle Cell Lymphoma marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies for the treatment of Mantle Cell Lymphoma?
• How many therapies are in-development by each company for Mantle Cell Lymphoma treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Mantle Cell Lymphoma treatment?
• What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Mantle Cell Lymphoma therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Mantle Cell Lymphoma and its status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Mantle Cell Lymphoma?
• What are the global historical and forecasted markets of Mantle Cell Lymphoma?

Reasons to buy

• The Patient Based Market Forecasting analysis will help in developing business strategies by understanding trends shaping and driving the Mantle Cell Lymphoma market
• Organize sales and marketing efforts by identifying the best opportunities for Mantle Cell Lymphoma in the US, Europe (Germany, France, Italy, and Spain) and the United Kingdom, and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the Mantle Cell Lymphoma market
• To understand the future market competition in the Mantle Cell Lymphoma market